Warren Regelmann, MD

Publications

 

ARTICLES: PUBLISHED or ACCEPTED

  1. Gemmell CG, Peterson PK, Regelmann WE, Schmeling D, Hoidal JR, and Quie. PG: Phagocytosis and killing of Streptococcus pyogenes by human alveolar macrophages. Infec. Immun. 32:1298-1300, 1981.
  2. Abramson JS, Mills EL, Sawyer MK, Regelmann WE, Nelson JD, and Quie PG: Recurrent infections and delayed separation of the umbilical cord in an infant with abnormal phagocytic cell locomotion and oxidative response during particle phagocytosis. J. Pediatr. 99:887-894, 1981.
  3. Regelmann WE: Recurrent infection in the child. Identification and evaluation of patients at risk for immunodeficiency. Postgrad. Med. 71:157-174, 1982.
  4. Regelmann WE, Gray ED, Quie PG, and Wannamaker LW: Characterization of the human cellular immune response to purified group A streptococcal blastogen A. J. Immunol. 128:1631-1636, 1982.
  5. Gray ED, Regelmann WE, Wannamaker LW, El Kholy A, and Abdin ZH: Functional alterations in non-T cells in rheumatic heart disease. Clin Exp. Immunol. 49:488-492, 1982.
  6. Payne NR, Hays NT, Regelmann WE, Sorenson M, Mills EL, and Quie PG: Growth in patients with chronic granulomatous disease. J. Pediatr. 102:397-399, 1983.
  7. Hays NT, Regelmann WE, and Quie PG: The use of rifampin in patients with chronic granulomatous disease of childhood: Clinical notes. Rev. Infect. Dis. 5:S522-S527, 1983.
  8. Gray ED, Peters G, Verstegen M, and Regelmann WE: Effect of extracellular slime substance from Staphylococcus epidermidis on the human cellular immune response. Lancet. I:1343-1346, 1986.
  9. Sirr SA, Elliott GR, Regelmann WE, Jeunemann PF, Morin RL, Boudreau RJ, Warwick WJ, and Loken MK: Aerosol penetration ratio: A new index of ventilation. J. Nucl. Med. 27:1342-1346, 1986.
  10. Regelmann WE, Lunde NM, Porter PT, and Quie PG: Increased monocyte chemiluminescence in cystic fibrosis patients and in their parents. Pediatr. Res. 20:619-622, 1986.
  11. Johnson GM, Lee DA, Regelmann WE, Gray ED, Peters G, and Quie PG: Interference with granulocyte function by Staphylococcus epidermidis slime. Infect. Immun. 54:13-20, 1986.
  12. Regelmann WE, Gray ED, Wannamaker LW, LeBien TW, Mansour M, El Kholy A, Abdin Z: Lymphocyte subpopulations in rheumatic heart disease. J. Rheumatology, 14:23-28, 1987.
  13. Gray ED, Regelmann WE, Abdin A, El Kholy A, Zaher R, Kamel R, Mansour M, Miller L, Ferrieri P, Zabriskie JB, and Braun D: Compartmentalization of cells bearing rheumatic cell surface antigens in peripheral blood and tonsils in rheumatic heart disease. J. Infect. Dis. 155:247-252, 1987.
  14. Devalon M, Elliott GR, and Regelmann WE: Oxidative response of human neutrophils, monocytes, and alveolar macrophages induced by unopsonized surface-adherent Staphylococcus aureus. Infect. Immun. 55:2398-2403, 1987.
  15. Gray ED, Abdin ZH, El Kholy A, Mansour M, Miller LC, Zaher S, Kamel R and Regelmann WE: Augmentation of cytotoxic activity by mitogens in rheumatic heart disease. J. Rheumatology, 15:1672-1676, 1988.
  16. Rich SS, Gray ED, Talbot R, Martin D, Zabriskie D, Braun D, Cairns L and Regelmann WE: Cell surface markers and cellular immune response associated with rheumatic heart disease: Complex segregation analysis. Genetic Epidemiology, 5:463-470, 1988.
  17. Regelmann WE, Talbot R, Cairns L, Martin D, Miller LC, Zabriski JB, Braun D, and Gray ED. Distribution of "Rheumatic" antigens in peripheral blood of RF/RHD patients and their families. J. Rheumatology, 16:931-935, 1989.
  18. Miller LC, Gray ED, Mansour M, Abdin ZH, Kamel R, Zaher S, Regelmann WE Cytokines and Immunoglobulin in Rheumatic Heart Disease: Production by blood and tonsilar mononuclear cells. J. Rheumatology, 16:1436-1442, 1989.
  19. Regelmann WE, Elliott GR, Clawson CC and Warwick WJ: Reduction of sputum Ps. aeruginosa density by antibiotics improves lung function in cystic fibrosis more than bronchodilators and chest physiotherapy alone. Am. Rev. Resp. Dis., 141:914-921, 1990.
  20. Abramson JS, Giebink GS, Regelmann WE, Kim Y, and Quie PG: C2 deficiency and recurrent infections. Pediatric Rev. Commun., 4: 141-146, 1990.
  21. Regelmann WE, Skubitz, KM and Herron JM: Increased monocyte oxidase activity in cystic fibrosis heterozygotes and homozygotes. Am. J. Resp. Cell Molecular Biol., 5:27-33, 1991.
  22. Glass JB, Sher PK, Lennon VA, and Regelmann, WE. The association of pauciarticular juvenile rheumatoid arthritis and myasthenia gravis. Am. J. Dis. Child., 145:1176-1180, 1991.
  23. Siefferman CM, Regelmann WE, Gray BH. Pseudomonas aeruginosa isolated from Cystic Fibrosis patients are killed by a bactericidal protein from human polymorphonuclear leukocytes. Infection and Immunity, 59:2152-2157, 1991.
  24. Kuni CC, Regelmann WE, duCret RP, Bourdeau RJ, Budd JR: Aerosol scintigraphy in the assessment of therapy for cystic fibrosis. Clinical Nuclear Medicine, 17(2):90-93, 1992.
  25. Schwarzenberg SJ, Freese KD, Regelmann WE, Gores PF, Boudreau RJ, Payne WD: Resolution of severe intrapulmonary shunting after liver transplantation. Chest, 103(4):1271-1273, 1993.
  26. Hudson VL, Wilenski C, Regelmann WE: Prognostic implications of initial oropharyngeal bacterial flora in patients diagnosed with cystic fibrosis before the age of two years. Journal of Pediatrics, 122(6):854-60, 1993.
  27. Regelmann WE: Diagnosing the cause of recurrent and persistent pneumonia in children. Pediatric Annals, 22(9):561-68, 1993.
  28. Fuchs, HJ, Borowitz, DS, Christiansen, DH, Morris, EM, Nash, ML, Rosenstein, BJ, Smith, AJ, Wohl, ME for the Pulmozyme (rhDNase) Study Group, Hudson, V. and Regelmann,WE, Univ. of Minnesota. Aerosolized recombinant human DNase reduces respiratory exacerbations and improves pulmonary function in patients with cytstic fibrosis. NEJM, 331:637-42, 1994.
  29. Regelmann WE, Siefferman CM, Schneider LA, Herron JM, Elliott GR, Clawson CC, Gray BH. Sputum peroxidase activity correlates with the severity of lung disease in Cystic Fibrosis. Pediatric Pulmonology, 19(1):1-9, 1995.
  30. Brottman, GM, Regelmann, WE, Slungaard, AA, Wangensteen, OD. The effect of eosinophil peroxidase on airway epithelial permeability in the guinea pig. Pediatric Pulmonology, 21(3):159-166, 1996.
  31. Wilmott RW, Amin RS, Colin AA, DeVault A, Dozor AJ, Eigen H, Johnson C, Lester LA, McCoy K, McKean LP, Moss R, Nash ML, Pagel Jue C, Regelmann WE, Stokes DC, Fuchs HJ. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Resp Crit Care Med, 153:1914-1917, 1996.
  32. Milla CE, Wielinski C, Regelmann WE. Clinical significance of the recovery of Aspergillus species from the respiratory secretions of cystic fibrosis patients. Pediatr Pulmonol, 21:6-10, 1996.
  33. Milla CE, Doherty L, Raatz S, Schwarzenberg SJ, Regelmann WE, Moran AM. The glycemic response to varying carbohydrate:fat ratios of dietary supplements in cystic fibrosis. J Parenteral Enteral Nutrition, 20(3):182-186, 1996.
  34. Shreve MR, Johnson S, Milla C, Wielenski C, Regelmann, WE. Polymerase chain reaction (PCR) based ribotyping and endonuclease subtyping are useful in determining Burkholderia (Pseudomonas) cepacia transmission and blood stream invasion in Cystic Fibrosis patients. Am J Resp Crit Care Med, in press, 1997.
  35. Regelmann WE, Schneider LA, Fahrenkrug S, Gray BH, Quam S, Herron JM, Clawson CC, Clawson DJ, Wangensteen, OD. Proteinase-free myeloperoxidase increases airway epithelial permeability in a whole trachea model. Submitted, Pediatr Pulmonol, 1997

 

MANUSCRIPTS SUBMITTED FOR PUBLICATION

  1. Regelmann, AG, Gray, BH, Haseman, J, Regelmann, WE. Elastin degradation and its inhibition by Cystic Fibrosis broncho-alveolar lavage are related to nutritional status. In revision, 1997
  2. Shreve, MR, Kaplowitz, H, Rabin, H, Stokes, D, Regelmann, WE.: A survey of microbiology practice supporting the diagnosis and management of infectious disease in cystic fibrosis. Pediatric Pulmonology, in press, 1997.

 

MANUSCRIPTS IN PREPARATION

  1. Milla, CE, Regelmann, WE. A novel method to study intrphagocytic bacterial killing.

 

CHAPTERS

  1. Quie PG, Mills EL, and Regelmann WE: Genetically Determined Abnormalities of Host Defense Against Bacterial Diseases. In: Microbiology 1979, D. Schlessinger (ed), American Society for Microbiology, 1979, pp 246-248.
  2. Mills EL, Regelmann WE, and Quie PG: Immunology of the Newborn. In: Textbook of Pediatric Infectious Diseases, RD Feigin and J Cherry (eds), WB Saunders Co, 1981, pp 729-746.
  3. Regelmann WE and Quie PG: Diagnosis and Management of immuno- deficiency in Children. In: The Management of Infectious Diseases in Clinical Practice, PK Peterson, LD Sabath, E Calderon, and AR Ronald (eds),Academic Press, New York, 1982, pp 359-370.
  4. Quie PG, Mills EL, Cates KL, Abramson JS, Regelmann WE, and Peterson PK: Functional Defects of Granulocytes and Susceptibility to Staphylococcal Disease. In: Staphylococci and Staphylococcal Disease vol I, CSF Easmon and C Adlam (eds), Academic Press, New York, 1983, pp
  5. Regelmann WE, Hays N, and Quie PG: Chronic Granulomatous Disease.In: Advances in Host Defense Mechanisms, vol III, JI Gallin and AS Fauci (eds), Raven Press, New York, 1983.
  6. Regelmann WE, Gray ED, Wannamaker LW, LeBien TW, Mansour M, El Kholy A, Abdin Z: Lymphocyte Subpopulations in Rheumatic Heart Disease. In: Recent Advances in Streptococci and Streptococcal Diseases, Proceedings of the IXth Lancefield International Symposium on Streptococci and Streptococcal Diseases, Mt. Fuji, Japan, September 1984. Y Kimura, S Kotami and Y Chiokawa (eds), Reedbooks Ltd, Berkshire, England, 1985, pp 338-339.
  7. Gray ED, Regelmann WE, Zabriskie JB, El Kholy A, Abdin A, Kamel RMH, Zaher SW: "Rheumatic" Cell Surface Antigens in. Peripheral Blood and Tonsils in Rheumatic Heart Disease. In: Recent Advances in Streptococci and Streptococcal Diseases, Proceedings of the IXth Lancefield International Symposium on Streptococci and StreptococcalDiseases, Mt. Fuji, Japan, September 1984. Y. Kimura, S. Kotami and Y.Chiokawa (eds), Reedbooks Ltd, Berkshire, England, 1985, pp 337-338.
  8. Regelmann WE, Mills EL, and Quie PG: Immunology of the Newborn. In: Textbook of Pediatric Infectious Diseases, 2nd edition, RD Feigin and J Cherry (eds), WB Saunders Co., New York, 1987, pp 921-939.
  9. Johnson GM, Regelmann WE, Gray ED, Peters G, and Quie PG: Staphylococcal Slime and Host Defenses: Effects on Polymorphonuclear Granulocytes. In: Pathogenicity and Clinical Significance of Coagulase-Negative Staphylococci, G Pulverer, PG Quie, and G Peters (eds), Gustav Fischer Verlag, Stuttgart, 1987, pp 33-44.
  10. Gray ED, Regelmann WE, and Peters G: Staphylococcal Slime and Host Defenses: Effects on Lymphocytes and Immune Function. In: Pathogenicity and Clinical Significance of Coagulase-Negative Staphylococci,G Pulverer, PG Quie, and G Peters (eds), Gustav Fisher Verlag, Stuttgart, 1987, pp 45-54.
  11. Regelmann WE, Elliott GE: Bronchoalveolar Lavage in Childhood Lung Disease. In: Pediatric Respiratory Disease: Diagnosis and Treatment, BC Hillman, ed., Grune & Stratton, Inc., Orlando, FL, 1992.

 

 

INVITED ARTICLES

  1. Regelmann WE: Human immunodeficiency virus infections in children: Prospect for Minnesota. Minnesota Med. 71(5):284-288, 1988.
  2. Belani D, Regelmann WE: Lyme disease in children. Rheumatic Disease Clinics of North America, 16:931-935, 1989.
  3. Regelmann WE, Filipovich A: "Lung Involvement in the Primary Immunodeficiency Syndromes." In: Seminars in Respiratory Medicine, Joseph Lynch, ed. Reviews in Respiratory Medicine, 1992.
  4. Regelmann WE: Diagnosing the cause of recurrent and persistent pneumonia in children. Pediatric Annals, 22(9):561-68, 1993.
  5. Regelmann WE: Oxygen therapy in children. Editorial. J. Pediatr, in press, 1995.

 

 

ABSTRACTS

  1. Regelmann WE, Giebink GS, Schiffman G, and Quie PG: Evidence for cell-mediated suppression of antibody response to pneumoccoccal polysaccharide type 7 and 23 in the chinchilla. American Society for Microbiology, May 1978.
  2. Regelmann WE, Gray ED, and Wannamaker LW: Analysis of cellular immune response to group A beta hemolytic streptococcal blastogen A. Lancefield Society, 1980.
  3. Regelmann WE, Lunde NM, and Quie PG: Increased monocyte chemiluminescence in cystic fibrosis patients and obligate carriers. Society for Pediatric Research, San Fransisco, California, April 28-May 1, 1981. Pediatr. Res. 15:729, 1981.
  4. Gray ED, Regelmann WE, El Kholy A, Abdin ZH, and Wannamaker LW: Cellular immune response to extracellular streptococcal products in rheumatic heart disease. VIIIth International Symposium on Streptococci and Streptococcal Diseases, Lund, Sweden, June 23-26, 1981.
  5. Regelmann WE, Gray ED, and Wannamaker LW: Human peripheral blood blastogenic response to group A streptococcal extracellular proteins. Lancefield Society, Chicago, Illinois, 1981.
  6. Elliott GR, Abramson JS, Regelmann WE, Verbrugh HA, and Quie PG: Defective phagocytic cell function in two infants with severe gram- negative abscess disease. Society for Pediatric Research, Pediatr. Res.16:329a, 1982.
  7. Regelmann WE, Lunde NM, and Quie PG: Monocytes from cystic fibrosis patients and carriers have increased chemiluminescence. American Thoracic Society, Los Angeles, California, 1982.
  8. Regelmann WE, Thomas PJ, Lunde NM, and Quie PG: Increased chemiluminescence in monocytes from cystic fibrosis patients and carriers. AmericanThoracic Society, Kansas City, Missouri, 1983.
  9. Regelmann WE, Thomas PJ, and Larson SA: Quantitative sputum bacteriology and pulmonary function testing in patients with cystic fibrosis. Society for Pediatric Research, Pediatr. Res. 17:388, 1983.
  10. Regelmann WE, Thomas PJ, Colburn T, Gray ED, and Giebink GS: Lymphocyte transformation response to purified streptolysin O and Streptococcus pneumoniae type 1. American Federation for Clinical Research, Clin. Res. 31:373a, 1983.
  11. Regelmann WE, Gray ED, Porter PT, Johnson GM, and Peters G: Staphylococcus epidermidis effects on bacterial opsonization and PMN leukocyte function. Society for Pediatric Research, San Fransisco, California, 1984.
  12. Regelmann WE, Thomas PJ, and Larson SA: Quantitative sputum bacteriology and pulmonary function testing in patients with cystic fibrosis. Pseudomonas aeruginosa: New therapeutic approaches from basic research. The University of British Columbia, British Columbia, Vancouver, Canada, 1984.
  13. Johnson GM, Regelmann WE, Gray ED, and Quie PG: Effects of Staphylococcus epidermidis slime on PMN chemotaxis and degranulation. 24th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1984.
  14. Regelmann WE, Gray ED, Wannamaker LW, LeBien TW, Mansour M, El Kholy A, and Abdin Z: Lymphocyte subpopulations in rheumatic heart disease. IXth Lancefield International Symposium on Streptococci and Streptococcal Disease, Japan, 1984.
  15. Gray ED, Regelmann WE, Zabriskie JB, El Kholy A, Abdin Z, Kamel RMH, and Zaher SW: "Rheumatic" cell surface antigens in peripheral blood and tonsils in rheumatic heart disease. IXth Lancefield International Symposium on Streptococci and Streptococcal Disease, Japan, 1984.
  16. Johnson GM, Lee DA, Regelmann WE, Gray ED, Peters G, and Quie PG: Staphylococcus epidermidis slime interferes with neutrophil phagocytosisand oxidative killing mechanisms. Society for Pediatric Research, Washington, DC, 1985.
  17. Regelmann WE, Lunde NM, Sirr SA, Elliott GR, and Warwick WJ: Effects of intensified chest physiotherapy on spirometry, regional ventilation, sputum bacterial load, and measures of inflammation in patients with cystic fibrosis with pulmonary exacerbation. American Federation for Clinical Research, Clin. Res. 33:471a, 1985.
  18. Devalon ML, Regelmann WE, Elliott GR, Peterson PK, and Quie PG: Oxidative metabolic response of human neutrophils (PMN) and alveolar macrophages (AM) to unopsonized surface-adherent Staphylococcus aureus. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, Minnesota, 1985.
  19. Regelmann WE and Herron JM: Increased lucigenin amplified chemiluminescence in cystic fibrosis carrier monoyctes. American Federation for Clinical Research, Washington, DC, 1986.
  20. Belani K, Clay ME, Johnson GM, and Regelmann WE: Neutrophil dysfunction in autoimmune neutropenia. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1986.
  21. Sirr SA, Regelmann WE, and Anderson QN: The significance of peripheral hot spots in radioaerosol scans in obstructive lung disease. Society of Nuclear Medicine, 34th Annual Meeting, Toronto, 1987.
  22. Regelmann WE, Gray ED, Zaher S, Kamel R, El Kholy A, Abdin Z, and Monsour M: Cytotoxic lymphocyte activity in rheumatic heart disease (RHD). Society for Pediatric Research, Anaheim, California, 1987.
  23. Regelmann WE and Herron J: Increased superoxide production after adhesion and Concanavalin A stimulation of cystic fibrosis heterozygote monocytes. North American CF Conference, Toronto, Canada, 1987.
  24. Regelmann WE and Herron J: Different reactive oxygen species produce different degrees of acridine orange intercalation into S. aureus DNA. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, 1987.
  25. Regelmann WE, Gray ED, Wannamaker LW, LeBien TW, Mansour M, El Kholy A, Abdin Z: Lymphocyte subpopulations in rheumatic heart disease, International Synopses, 1987.
  26. Regelmann WE, Gray ED, Talbot R, Cairns L, Martin D, Miller LC, Zabriskie JB, Braun D, and Rich SS: Distribution and inheritance of "Rheumatic antigens in peripheral blood of RHD patients and their families. Xth Lancefield International Symposium on Streptococci and Streptococcal Diseases, Cologne, 1987.
  27. Regelmann WE, Gray ED, Talbot R, Cairns L, Miller LC, and Rich SS. Proliferative response of mononuclear cells from blood to streptococcalblastogen A in RHD patients and their families. Xth Lancefield International Symposium on Streptococci and Streptococcal Diseases, Cologne, 1987.
  28. Regelmann WE, Erdahl L, and Herron J: Pseudomonas aeruginosa mucoid exopolysaccharide decreases the antimicrobic activity of myeloperoxidase. American Federation for Clinical Research, Chicago, Illinois, 1987.
  29. Regelmann WE, Elliott GR, Clawson CC, Warwick WJ: Reduction of sputum Ps. aeruginosa density by antibiotics improves lung function in CF more than bronchodilators and chest physiotherapy alone. North American CF Conference, Orlando, Florida, 1988.
  30. Regelmann WE, Elliott GR, Clawson CC, Warwick WJ: Reduction of Ps..aeruginosa density improves lung function in CF more than bronchodilators and chest physiotherapy (CP) alone. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, California, 1988.
  31. Regelmann WE, Elliott GR, Clawson CC, Warwick WJ: Reduction of Ps. aeruginosa Density in Sputum Improves Lung Function in CF more than Bronchodilators and Chest Physiotherapy (CP) Alone. Northwestern Pediatric Society, September 30, 1988.
  32. Kuni CC, Budd JR, Regelmann WE, Boudreau RJ, duCret RP, Wielinski CL: Correlation of Tc-99m-DPTA aerosol ventilation studies with pulmonary function testing in patients with cystic fibrosis. 74th Scientific Assembly of The Radiological Society of North America, 1988.
  33. Elliott GR, Clawson CC, Garlich DJ, Regelmann WE: Influence of bronchoalveolar lavage fluid from cystic fibrosis (CF) patients on uptake of Staphylococcus aureus by normal PMN. American Thoracic Society, 1989.
  34. Regelmann WE, Herron J, Siefferman C, Elliott GR, Clawson CC: Increased sputum peroxidase activity is associated with increased pulmonary disease in cystic fibrosis. American Thoracic Society, 1989.
  35. Regelmann WE, Lam P, Herron J: Increased oxygen consumption by monocytes from cystic fibrosis heterozygotes. American Thoracic Society, 1989.
  36. Regelmann WE, Wilenski C: Does pharyngeal microbiology at diagnosis define Cystic Fibrosis patients at high risk for pulmonary mortality and morbidity? North American Cystic Fibrosis Conference, Tarpon Springs, FL 1989.
  37. Belani K, and Regelmann WE: Usefulness of anti-Borrelia antibody titers to predict response to antibiotics in children. Interscience Congress on Antimicrobic Agents and Chemotherapy, Houston, TX 1989.
  38. Regelmann WE and Herron, J: CR3 mediated monocyte oxidative response is increased in cystic fibrosis heterozygotes. American Thoracic Society, 1990.
  39. Hudson VL, Wielinski CL, Orr HT and Regelmann WE: The delta F508 mutation in the CFTR gene is not associated with structural lung disease in CF. 4th Annual North American & 1990 International Cystic Fibrosis Conference, Arlington, VA, 1990.
  40. Hudson V, Quam S, and Regelmann WE. Blockade of complement receptor type 3 (CR3) inhibits killing of Streptococcus pneumoniae type 6A by polymorphonuclear leukocytes. American Thoracic Society, 1991
  41. Hudson VL, Moran A, Orr HT, and Regelmann WE. Mutations DF508, G551D and G542X are associated with pancreatic endocrine dysfunction in patients with CF. Pediatr. Pulm. S6:249, 1991
  42. Brottman GM, Schneider L, Gray B, Wangensteen OD, and Regelmann WE. The effect of myeloperoxidase (MPO) on tracheal epithelial permeability. Pediatr. Pulm. S6:300, 1991
  43. Hudson VL, Regelmann WE, Kuni CC and duCret RP. 99mTC-DTPA aerosol lung scans detect persistent lung defects in young CF patients before abnormalities appear in chest radiographs and spirometry. Am Rev Resp Dis 145:A553, 1991
  44. McCracken MJ, Regelmann WE, Kujawa S. Transmission of Pseudomonas aeruginosa and staphylococcus aureus in cystic fibrosis adolescents. Pediatr Pulm S8:291, 1992 and Proceedings, XIth International Cystic Fibrosis Congress, 1992
  45. Brottman GM, Wielinski C, Regelmann WE. The relationship between genotype and immunoglobulin G and IgG subclasses in cystic fibrosis. Proceedings, XIth International Cystic Fibrosis Congress, 1992
  46. Milla CE, Wielinski C, Regelmann WE. Comparison of the decline in pulmonary function in deceased cystic fibrosis (CF) patients homozygous for the F508 mutation versus compound heterozygotes for the F508 mutation. Am Rev Resp Dis 147:A464, 1993
  47. Milla CE, Wielinski C, Regelmann WE. The distribution of the F508 mutation in a group of deceased cystic fibrosis (CF) patients. Am Rev Resp Dis 147:A579, 1993
  48. Pryor M, Regelmann WE, Jessurun J, Warwick WJ. Use of a negative pressure technique on transbronchial biopsy specimens in lung transplant recipients. Am Rev Resp Dis 147:A338, 1993
  49. Regelmann AG, Gray BH, Haseman JR, Regelmann WE. Elastin Degradation and its Inhibition by Cystic Fibrosis Broncho-Alveolar lavage. Pediatric Research 35:397A, 1994
  50. Milla, CE, Regelmann, WE. Development of a novel method to study intraphagocytic bacterial killing. Society for Pediatric Research, 1995
  51. Shreve MR, Johnson S, Milla C, Wielenski C, Regelmann, WE. Polymerase chain reaction (PCR) based ribotyping and endonuclease subtyping are useful in determining Burkhoderia (Pseudomonas) cepacia transmission and blood stream invasion in Cystic Fibrosis patients. Am J Respir Crit Care Med, 151(4):A740, 1995
  52. Milla CE, Doherty L, Raatz S, Schwarzenberg SJ, Regelmann WE, Moran A: Glycemic and respiratory responses to enteral formulas containing varying amounts of fat and carbohydrate in a group of cystic fibrosis (CF) patients with severe pulmonary function impairment. Pediatric Pulmonology, Suppl 12:A292, 1995
  53. Shreve M, Johnson S, Milla CE, Wielinski CL, Regelmann WE: Ribotyping and endonuclease subtyping in the epidemiology of Burkholderia cepacia. Am J Respir Crit Care Med, 153(4):A706, 1996
  54. Shreve M, Milla CE, Johnson S, Regelmann WE: Suitability of techniques of P. aeruginosa DNA fingerprinting to determine risk of acquisition in cystic fibrosis. Am J Respir Crit Care Med, 1997

 

Abstract Submitted

return to Dr. Regelmann's page
 
return to U of MN:PCCM home page